Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis

Figure 2

Network plots the effect of DMTs on the risk of acquiring COVID-19 and its severity. Platform therapy: interferon and glatiramer acetate; anti-CD20 agents: rituximab and ocrelizumab. (a) Risk of acquiring infection based on a univariate model. (b) Risk of acquiring infection based on a multivariate model. (c) Risk of severe infection based on a univariate model. (d) Risk of severe infection based on a multivariate model.

(a)

(b)

(c)

(d)